Overview

Efficacy and Safety Study of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Using a Novel Bi-directional Device

Status:
Completed

Trial end date:
2015-07-03

Target enrollment:

Participant gender:

Summary

The primary objective of this study was to compare the efficacy of intranasal administration of 100, 200, and 400 μg twice daily (bid) of fluticasone propionate, delivered by the Optinose device, with matching placebo in subjects with bilateral nasal polyposis and nasal congestion.

Phase:

Phase 3

Details

Lead Sponsor:

Optinose US Inc.

Treatments:

Fluticasone
Xhance